爱豆传媒

December 28, 2022

YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAI鈥橲 SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS

December 23, 2022

ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER

December 23, 2022

EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

December 22, 2022

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

December 20, 2022

EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA庐 (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS

December 16, 2022

EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM

December 15, 2022

EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES

December 1, 2022

EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM

November 30, 2022

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER鈥橲 DISEASE AT CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE (CTAD) CONFERENCE

November 30, 2022

ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER鈥橲 DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

November 29, 2022

(REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER

November 29, 2022

EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT庐 FOR TREATMENT OF DEMENTIA WITH LEWY BODIES

November 24, 2022

EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

November 22, 2022

To Develop Japan鈥檚 First Blood Biomarker-Based Diagnostic Workflow for Dementia
Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

November 21, 2022

EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER鈥橲 DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

November 16, 2022

METOJECT庐 SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS

November 7, 2022

EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL庐 AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON庐 IN ASIA TO DKSH

November 4, 2022

EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMER鈥橲 DISEASE, IN THAILAND

November 2, 2022

EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON庐

October 31, 2022

EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT庐 FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION

October 4, 2022

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS

September 28, 2022

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER鈥橲 DISEASE

September 26, 2022

Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange
(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act)

September 26, 2022

METOJECT庐 SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS

September 21, 2022

RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER鈥橲 DAY, SEPTEMBER 21
鈥淟EARNING HELPS US TO BE KIND鈥� LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP

September 12, 2022

Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022

September 12, 2022

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN庐) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies

September 6, 2022

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination鈥檚 Potential Across Difficult-to-Treat Cancers

Post-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulin鈥檚 Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai鈥檚 Commitment to Advancing Understanding of Our Medicines

August 30, 2022

SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA庐 INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION

August 24, 2022

EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS

August 12, 2022

HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH

August 9, 2022

EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE

August 4, 2022

EISAI PRESENTS NEW FINDINGS ON LECANEMAB鈥橲 INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

August 3, 2022

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

July 26, 2022

EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT

July 26, 2022

EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER鈥橲 DISEASE RESEARCH AT THE ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

July 25, 2022

A螔-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE

July 15, 2022

REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS <effective as of July 15, 2022>

July 6, 2022

THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI鈥橲 BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER鈥橲 DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

June 29, 2022

Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares

June 28, 2022

E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF 鈥淚MPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING鈥�

June 24, 2022

EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP 鈥淜IGALI DECLARATION鈥� FOR ELIMINATING NEGLECTED TROPICAL DISEASES
CEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES

June 22, 2022

EISAI鈥橲 鈥淣OUKNOW庐鈥�, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY

June 22, 2022

EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling

June 8, 2022

Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023

June 6, 2022

EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING
Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)

Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090)

June 3, 2022

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING

May 30, 2022

Announcement of a Summary Share Exchange (kan鈥檌 kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary

May 27, 2022

EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai鈥檚 Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients
銆赌
Presentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information 爱豆传媒 Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma

May 27, 2022

MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS

May 20, 2022

鈥淢OVICOL庐 HD鈥� Launched
A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan

May 13, 2022

Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System

May 13, 2022

Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System

May 13, 2022

Notification Regarding Partial Amendment to the Articles of Incorporation

May 13, 2022

CHANGES OF CORPORATE OFFICERS

May 10, 2022

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER鈥橲 DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

May 10, 2022

EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN

May 3, 2022

Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022

April 27, 2022

Discontinuance (abolition) of the Policy for Protection of the Company鈥檚 Corporate Value and Common Interests of Shareholders

April 27, 2022

LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER鈥橲 DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY

April 8, 2022

EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES鈥� NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER鈥橲 DISEASE

April 1, 2022

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

March 28, 2022

Announcement about an approval for additional indication of Jyseleca庐, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
Approval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis

March 22, 2022

Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer鈥檚 Disease
The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)

March 22, 2022

LATEST FINDINGS ON LECANEMAB 鈥� CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS 鈥� PRESENTED AT AD/PD鈩� 2022 ANNUAL MEETING

March 15, 2022

ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER鈥楽 DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN

March 15, 2022

Biogen and Eisai amend collaboration agreements on Alzheimer鈥檚 disease treatments

March 11, 2022

EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD鈩� 2022 ANNUAL MEETING

March 9, 2022

EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)

March 7, 2022

LENVIMA庐锛圠ENVATINIB锛塈N COMBINATION WITH KEYTRUDA庐锛圥EMBROLIZUMAB锛堿PPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION

March 4, 2022

EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB

February 25, 2022

LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Results From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib

LENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer

February 10, 2022

EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES鈥� PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER鈥橲 DISEASE

February 1, 2022

EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR庐 2021

January 31, 2022

LENVIMA庐锛圠ENVATINIB锛塈N COMBINATION WITH KEYTRUDA庐锛圥EMBROLIZUMAB锛堿PPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

January 28, 2022

EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES
10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP 鈥淟ONDON DECLARATION鈥�

January 28, 2022

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM庐

January 20, 2022

Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine

January 19, 2022

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

January 19, 2022

FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI鈥橲 ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
EISAI鈥橲 ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY

January 17, 2022

EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM

January 13, 2022

Eisai鈥檚 Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer鈥檚 Disease

January 13, 2022

EISAI TO LAUNCH DIGITAL TOOL 鈥淐ogMate鈩⑩�� IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH)

January 6, 2022

EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR